RxDoctor Payments Data

Jaime Wilson, NP

Family · Bristol, TNNPI 1538689542

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 141 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$826
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$368
  • Esperion Therapeutics, Inc.$202
  • AstraZeneca$174
  • Amgen$144
  • Novocure Inc.$129
  • plus $874 from 15 others

What the payments were for

  • Food & beverage$2,60496%
  • Education$1134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$15,927
Medicare patients
87
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$26,364
Ranolazine ErRanolazine15$1,320
Ondansetron Hcl50$859
Prochlorperazine Maleate56$690
Hydroxyurea46$560
Dexamethasone40$482
Bisoprolol Fumarate14$404
Ondansetron OdtOndansetron13$318
Doxycycline Hyclate12$271
Anastrozole16$212
Pantoprazole Sodium11$165
Metoprolol Succinate16$161
Gabapentin11$128
Potassium Chloride16$124
Atorvastatin Calcium14$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$26,36432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →